Cosmetic patent and female invention.
Majority customers of cosmetics are female. Would this imply a high proportion of inventors of cosmetics technology is female? Would the inventor's gender be related to the characteristics and quality...
Protein-arginine N-methyltransferases : Questions médicales fréquentes
Questions fréquentes et termes MeSH associés
Diagnostic 5
#1
Comment diagnostiquer une dysfonction des N-méthyltransférases ?
Des tests génétiques et des analyses biochimiques peuvent être utilisés pour diagnostiquer.
#2
Quels tests sont utilisés pour évaluer l'activité enzymatique ?
Des tests enzymatiques spécifiques mesurent l'activité des N-méthyltransférases dans les échantillons.
#3
Y a-t-il des biomarqueurs associés à ces enzymes ?
Des biomarqueurs comme la méthylation de l'arginine peuvent indiquer une activité enzymatique.
#4
Quels symptômes peuvent indiquer un problème enzymatique ?
Des symptômes variés comme des troubles neurologiques ou immunitaires peuvent survenir.
#5
Comment les tests génétiques aident-ils au diagnostic ?
Ils identifient des mutations spécifiques dans les gènes codant pour ces enzymes.
Symptômes 5
#1
Quels sont les symptômes d'une carence en N-méthyltransférases ?
Les symptômes incluent fatigue, troubles cognitifs et anomalies immunitaires.
#2
Les troubles de l'humeur sont-ils liés à ces enzymes ?
Oui, des déséquilibres peuvent affecter l'humeur et contribuer à des troubles psychiatriques.
#3
Peut-on observer des symptômes neurologiques ?
Oui, des troubles neurologiques comme des convulsions peuvent être présents.
#4
Y a-t-il des symptômes spécifiques chez les enfants ?
Les enfants peuvent présenter des retards de développement et des troubles d'apprentissage.
#5
Comment les symptômes varient-ils selon l'âge ?
Les symptômes peuvent être plus prononcés chez les jeunes enfants et les personnes âgées.
Prévention 5
#1
Comment prévenir les troubles liés aux N-méthyltransférases ?
Une alimentation équilibrée et un mode de vie sain peuvent aider à prévenir ces troubles.
#2
Y a-t-il des mesures préventives spécifiques ?
Des dépistages précoces et des conseils génétiques peuvent être bénéfiques.
#3
L'éducation sur la santé est-elle importante ?
Oui, sensibiliser les patients et les familles peut aider à identifier les symptômes tôt.
#4
Les vaccinations jouent-elles un rôle préventif ?
Certaines vaccinations peuvent prévenir des infections qui aggravent les symptômes.
#5
Comment le suivi médical aide-t-il à la prévention ?
Un suivi régulier permet de surveiller l'état de santé et d'ajuster les traitements.
Traitements 5
#1
Quels traitements existent pour les dysfonctionnements enzymatiques ?
Les traitements peuvent inclure des suppléments nutritionnels et des thérapies ciblées.
#2
Les médicaments peuvent-ils aider à réguler ces enzymes ?
Oui, certains médicaments peuvent moduler l'activité des N-méthyltransférases.
#3
Y a-t-il des thérapies géniques disponibles ?
Des recherches sont en cours sur les thérapies géniques pour corriger les mutations.
#4
Comment la nutrition influence-t-elle le traitement ?
Une alimentation riche en nutriments peut soutenir la fonction enzymatique.
#5
Les traitements sont-ils personnalisés ?
Oui, les traitements peuvent être adaptés en fonction des besoins individuels du patient.
Complications 5
#1
Quelles complications peuvent survenir avec ces troubles ?
Des complications neurologiques, immunitaires et métaboliques peuvent se développer.
#2
Les troubles cardiovasculaires sont-ils possibles ?
Oui, des déséquilibres peuvent augmenter le risque de maladies cardiovasculaires.
#3
Comment les complications affectent-elles la qualité de vie ?
Elles peuvent entraîner des limitations fonctionnelles et des besoins de soins accrus.
#4
Y a-t-il des complications à long terme ?
Oui, des complications chroniques peuvent affecter la santé globale et le bien-être.
#5
Les complications peuvent-elles être évitées ?
Certaines complications peuvent être évitées par un traitement précoce et approprié.
Facteurs de risque 5
#1
Quels sont les facteurs de risque associés ?
Les facteurs incluent des antécédents familiaux, des mutations génétiques et des carences nutritionnelles.
#2
L'environnement joue-t-il un rôle ?
Oui, des facteurs environnementaux comme la pollution peuvent influencer la fonction enzymatique.
#3
Le mode de vie affecte-t-il le risque ?
Un mode de vie sédentaire et une mauvaise alimentation augmentent le risque de troubles.
#4
Les infections peuvent-elles être un facteur de risque ?
Certaines infections peuvent exacerber les symptômes et augmenter le risque de complications.
#5
Y a-t-il des groupes à risque spécifiques ?
Les personnes avec des antécédents familiaux ou des troubles métaboliques sont plus à risque.
Contenu validé par Dr Olivier Menir
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
Validation scientifique effectuée le 23/03/2025
Contenu vérifié selon les dernières recommandations médicales
Auteurs principaux
Y George Zheng
4 publications dans cette catégorie
Affiliations :
- Department of Pharmaceutical and Biomedical Sciences, University of Georgia, Athens, GA 30602, United States. yzheng@uga.edu.
Publications dans "Protein-arginine N-methyltransferases" :
-
Protein arginine methyltransferase 6 is a novel substrate of protein arginine methyltransferase 1.
World journal of biological chemistry
-
The macromolecular complexes of histones affect protein arginine methyltransferase activities.
The Journal of biological chemistry 2021-09-06
-
Protein arginine methyltransferases: insights into the enzyme structure and mechanism at the atomic level.
Cellular and molecular life sciences : CMLS 2019-05-23
-
Hetero-oligomeric interaction as a new regulatory mechanism for protein arginine methyltransferases.
Biochemical Society transactions 2024-09-26
Adam Frankel
4 publications dans cette catégorie
Affiliations :
- Faculty of Pharmaceutical Sciences, The University of British Columbia, Vancouver, British Columbia, Canada. Electronic address: adam.frankel@ubc.ca.
Publications dans "Protein-arginine N-methyltransferases" :
-
Protein arginine N-methyltransferase 2 plays a noncatalytic role in the histone methylation activity of PRMT1.
The Journal of biological chemistry 2023-10-19
-
The application of differential scanning fluorimetry in exploring bisubstrate binding to protein arginine N-methyltransferase 1.
Methods (San Diego, Calif.) 2019-11-11
-
Protein arginine N-methyltransferase activity determination with filter binding and phosphor screening (FBAPS) assay.
Analytical biochemistry 2022-06-13
-
Protein Arginine Methyltransferases in Cardiovascular and Neuronal Function.
Molecular neurobiology 2019-12-10
Alessandra Feoli
3 publications dans cette catégorie
Affiliations :
- Department of Pharmacy, Epigenetic Med Chem Lab, University of Salerno, via Giovanni Paolo II 132, Fisciano ,I-84084 SA Italy.
Publications dans "Protein-arginine N-methyltransferases" :
-
Identification of a Protein Arginine Methyltransferase 7 (PRMT7)/Protein Arginine Methyltransferase 9 (PRMT9) Inhibitor.
Journal of medicinal chemistry 2023-08-10
-
Turning Nonselective Inhibitors of Type I Protein Arginine Methyltransferases into Potent and Selective Inhibitors of Protein Arginine Methyltransferase 4 through a Deconstruction-Reconstruction and Fragment-Growing Approach.
Journal of medicinal chemistry 2022-04-28
-
Prodrug Approach to Exploit (S) Alanine as Arginine Mimic Moiety in the Development of Protein Arginine Methyltransferase 4 Inhibitors.
ChemMedChem 2024-05-16
Giulia Iannelli
3 publications dans cette catégorie
Affiliations :
- Department of Pharmacy, Epigenetic Med Chem Lab, University of Salerno, via Giovanni Paolo II 132, Fisciano ,I-84084 SA Italy.
- PhD Program in Drug Discovery and Development, University of Salerno, via Giovanni Paolo II 132, Fisciano ,I-84084 SA Italy.
Publications dans "Protein-arginine N-methyltransferases" :
-
Identification of a Protein Arginine Methyltransferase 7 (PRMT7)/Protein Arginine Methyltransferase 9 (PRMT9) Inhibitor.
Journal of medicinal chemistry 2023-08-10
-
Turning Nonselective Inhibitors of Type I Protein Arginine Methyltransferases into Potent and Selective Inhibitors of Protein Arginine Methyltransferase 4 through a Deconstruction-Reconstruction and Fragment-Growing Approach.
Journal of medicinal chemistry 2022-04-28
-
Prodrug Approach to Exploit (S) Alanine as Arginine Mimic Moiety in the Development of Protein Arginine Methyltransferase 4 Inhibitors.
ChemMedChem 2024-05-16
Alessandra Cipriano
3 publications dans cette catégorie
Affiliations :
- Department of Pharmacy, Epigenetic Med Chem Lab, University of Salerno, via Giovanni Paolo II 132, Fisciano ,I-84084 SA Italy.
Publications dans "Protein-arginine N-methyltransferases" :
-
Identification of a Protein Arginine Methyltransferase 7 (PRMT7)/Protein Arginine Methyltransferase 9 (PRMT9) Inhibitor.
Journal of medicinal chemistry 2023-08-10
-
Turning Nonselective Inhibitors of Type I Protein Arginine Methyltransferases into Potent and Selective Inhibitors of Protein Arginine Methyltransferase 4 through a Deconstruction-Reconstruction and Fragment-Growing Approach.
Journal of medicinal chemistry 2022-04-28
-
Prodrug Approach to Exploit (S) Alanine as Arginine Mimic Moiety in the Development of Protein Arginine Methyltransferase 4 Inhibitors.
ChemMedChem 2024-05-16
Ciro Milite
3 publications dans cette catégorie
Affiliations :
- Department of Pharmacy, Epigenetic Med Chem Lab, University of Salerno, via Giovanni Paolo II 132, Fisciano ,I-84084 SA Italy.
Publications dans "Protein-arginine N-methyltransferases" :
-
Identification of a Protein Arginine Methyltransferase 7 (PRMT7)/Protein Arginine Methyltransferase 9 (PRMT9) Inhibitor.
Journal of medicinal chemistry 2023-08-10
-
Turning Nonselective Inhibitors of Type I Protein Arginine Methyltransferases into Potent and Selective Inhibitors of Protein Arginine Methyltransferase 4 through a Deconstruction-Reconstruction and Fragment-Growing Approach.
Journal of medicinal chemistry 2022-04-28
-
Prodrug Approach to Exploit (S) Alanine as Arginine Mimic Moiety in the Development of Protein Arginine Methyltransferase 4 Inhibitors.
ChemMedChem 2024-05-16
Monica Viviano
3 publications dans cette catégorie
Affiliations :
- Department of Pharmacy, Epigenetic Med Chem Lab, University of Salerno, via Giovanni Paolo II 132, Fisciano ,I-84084 SA Italy.
Publications dans "Protein-arginine N-methyltransferases" :
-
Identification of a Protein Arginine Methyltransferase 7 (PRMT7)/Protein Arginine Methyltransferase 9 (PRMT9) Inhibitor.
Journal of medicinal chemistry 2023-08-10
-
Turning Nonselective Inhibitors of Type I Protein Arginine Methyltransferases into Potent and Selective Inhibitors of Protein Arginine Methyltransferase 4 through a Deconstruction-Reconstruction and Fragment-Growing Approach.
Journal of medicinal chemistry 2022-04-28
-
Prodrug Approach to Exploit (S) Alanine as Arginine Mimic Moiety in the Development of Protein Arginine Methyltransferase 4 Inhibitors.
ChemMedChem 2024-05-16
Sabrina Castellano
3 publications dans cette catégorie
Affiliations :
- Department of Pharmacy, Epigenetic Med Chem Lab, University of Salerno, via Giovanni Paolo II 132, Fisciano ,I-84084 SA Italy.
Publications dans "Protein-arginine N-methyltransferases" :
-
Identification of a Protein Arginine Methyltransferase 7 (PRMT7)/Protein Arginine Methyltransferase 9 (PRMT9) Inhibitor.
Journal of medicinal chemistry 2023-08-10
-
Turning Nonselective Inhibitors of Type I Protein Arginine Methyltransferases into Potent and Selective Inhibitors of Protein Arginine Methyltransferase 4 through a Deconstruction-Reconstruction and Fragment-Growing Approach.
Journal of medicinal chemistry 2022-04-28
-
Prodrug Approach to Exploit (S) Alanine as Arginine Mimic Moiety in the Development of Protein Arginine Methyltransferase 4 Inhibitors.
ChemMedChem 2024-05-16
Gianluca Sbardella
3 publications dans cette catégorie
Affiliations :
- Department of Pharmacy, Epigenetic Med Chem Lab, University of Salerno, via Giovanni Paolo II 132, Fisciano ,I-84084 SA Italy.
Publications dans "Protein-arginine N-methyltransferases" :
-
Identification of a Protein Arginine Methyltransferase 7 (PRMT7)/Protein Arginine Methyltransferase 9 (PRMT9) Inhibitor.
Journal of medicinal chemistry 2023-08-10
-
Turning Nonselective Inhibitors of Type I Protein Arginine Methyltransferases into Potent and Selective Inhibitors of Protein Arginine Methyltransferase 4 through a Deconstruction-Reconstruction and Fragment-Growing Approach.
Journal of medicinal chemistry 2022-04-28
-
Prodrug Approach to Exploit (S) Alanine as Arginine Mimic Moiety in the Development of Protein Arginine Methyltransferase 4 Inhibitors.
ChemMedChem 2024-05-16
Rong Huang
3 publications dans cette catégorie
Affiliations :
- Department of Medicinal Chemistry and Molecular Pharmacology, Center for Cancer Research, Institute for Drug Discovery, Purdue University, West Lafayette, IN 47907, United States.
Publications dans "Protein-arginine N-methyltransferases" :
-
Non-Histone Arginine Methylation by Protein Arginine Methyltransferases.
Current protein & peptide science
-
A Pan-Inhibitor for Protein Arginine Methyltransferase Family Enzymes.
Biomolecules 2021-06-08
-
Chemical Biology of Protein N-Terminal Methyltransferases.
Chembiochem : a European journal of chemical biology 2019-02-13
Shougang Zhuang
3 publications dans cette catégorie
Affiliations :
- Department of Medicine, Rhode Island Hospital and Alpert Medical School, Brown University, Providence, RI, U.S.A.
- Department of Nephrology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China.
Publications dans "Protein-arginine N-methyltransferases" :
-
The role of protein arginine methyltransferases in kidney diseases.
Clinical science (London, England : 1979)
-
Protein arginine methyltransferases in renal development, injury, repair, and fibrosis.
Frontiers in pharmacology 2023-02-03
-
The Role and Mechanism of Lysine Methyltransferase and Arginine Methyltransferase in Kidney Diseases.
Frontiers in pharmacology 2022-04-26
Jong-Sun Kang
3 publications dans cette catégorie
Affiliations :
- Department of Molecular Cell Biology, School of Medicine, Sungkyunkwan University, Suwon 16419, Korea.
- Single Cell Network Research Center, Sungkyunkwan University, Suwon 16419, Korea.
Publications dans "Protein-arginine N-methyltransferases" :
-
Protein Arginine Methyltransferases in Neuromuscular Function and Diseases.
Cells 2022-01-21
-
Role of Protein Arginine Methyltransferases and Inflammation in Muscle Pathophysiology.
Frontiers in physiology 2021-08-19
-
Protein Arginine Methyltransferases: Emerging Targets in Cardiovascular and Metabolic Disease.
Diabetes & metabolism journal 2024-07-24
Giuliana Sarno
2 publications dans cette catégorie
Affiliations :
- Department of Pharmacy, Epigenetic Med Chem Lab, University of Salerno, via Giovanni Paolo II 132, Fisciano ,I-84084 SA Italy.
- PhD Program in Drug Discovery and Development, University of Salerno, via Giovanni Paolo II 132, Fisciano ,I-84084 SA Italy.
Publications dans "Protein-arginine N-methyltransferases" :
-
Identification of a Protein Arginine Methyltransferase 7 (PRMT7)/Protein Arginine Methyltransferase 9 (PRMT9) Inhibitor.
Journal of medicinal chemistry 2023-08-10
-
Prodrug Approach to Exploit (S) Alanine as Arginine Mimic Moiety in the Development of Protein Arginine Methyltransferase 4 Inhibitors.
ChemMedChem 2024-05-16
Steven G Clarke
2 publications dans cette catégorie
Affiliations :
- Department of Chemistry and Biochemistry, and the Molecular Biology Institute, University of California, Los Angeles, California 90095, United States.
Publications dans "Protein-arginine N-methyltransferases" :
-
Identification of a Protein Arginine Methyltransferase 7 (PRMT7)/Protein Arginine Methyltransferase 9 (PRMT9) Inhibitor.
Journal of medicinal chemistry 2023-08-10
-
PRMT7 as a unique member of the protein arginine methyltransferase family: A review.
Archives of biochemistry and biophysics 2019-02-22
Yandong Lai
2 publications dans cette catégorie
Affiliations :
- Pulmonary, Allergy, and Critical Care Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
Publications dans "Protein-arginine N-methyltransferases" :
Xiuying Li
2 publications dans cette catégorie
Affiliations :
- Pulmonary, Allergy, and Critical Care Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
- Veterans Affairs Pittsburgh Healthcare system, Pittsburgh, Pennsylvania, USA.
Publications dans "Protein-arginine N-methyltransferases" :
Tiao Li
2 publications dans cette catégorie
Affiliations :
- Pulmonary, Allergy, and Critical Care Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
Publications dans "Protein-arginine N-methyltransferases" :
Toru Nyunoya
2 publications dans cette catégorie
Affiliations :
- Pulmonary, Allergy, and Critical Care Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
- Veterans Affairs Pittsburgh Healthcare system, Pittsburgh, Pennsylvania, USA.
Publications dans "Protein-arginine N-methyltransferases" :
Kong Chen
2 publications dans cette catégorie
Affiliations :
- Pulmonary, Allergy, and Critical Care Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
Publications dans "Protein-arginine N-methyltransferases" :
Yingze Zhang
2 publications dans cette catégorie
Affiliations :
- Pulmonary, Allergy, and Critical Care Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
Publications dans "Protein-arginine N-methyltransferases" :
Sources (4448 au total)
Patent highlights August-September 2023.
A snapshot of noteworthy recent developments in the patent literature of relevance to pharmaceutical and medical research and development....
Patent Highlights June-July 2023.
A snapshot of noteworthy recent developments in the patent literature of relevance to pharmaceutical and medical research and development....
Patent highlights October-November 2023.
A snapshot of noteworthy recent developments in the patent literature of relevance to pharmaceutical and medical research and development....
A patent review of MAT2a inhibitors (2018-2021).
In methylthioadenosine phosphorylase (MTAP)-deficient tumor cells, reduced S-adenosylmethionine (SAM) levels in the context of elevated methylthioadenosine (MTA) has been hypothesized to lead to inhib... This review covers patent applications between January 2018 and December 2021. 18 patent applications from 5 different applicants are evaluated.... Recent advances in the field show a significant interest in the MAT2a therapeutic hypothesis. Agios and Ideaya in particular have capitalized on an allosteric binding mode first published by Pfizer in...
Influencing factors, evolution, and strategies for improving the quality of traditional Chinese medicine patents: an empirical study based on patent invalidation cases.
This study analyzes 134 invalidated traditional Chinese medicine (TCM) patents from 1984 to 2021 to explore common weaknesses and track quality progression. The findings highlight that TCM patents app...
Are patents important indicators of innovation for Chagas disease treatment?
Chagas disease is a neglected, endemic disease in 21 countries, spreading to non-endemic countries too. Like other neglected diseases affecting primarily low- and middle-income countries, low investme... The author focused specifically on patents for the treatment, the new candidates disclosed in the patents, and the barriers to innovation.... Patents in Chagas disease have been increasing in the last years, although they do not bring new compounds to an effective treatment....
A patent review of anticancer CDK2 inhibitors (2017-present).
The success of the CDK4/6 inhibitor Ibrance™ (Palbociclib) as an anticancer agent inspired and directed more efforts toward the discovery of selective cyclin-dependent kinase (CDKs) inhibitors. CDK2 i... This review covers the patent literature of CDK2 inhibitors published between 2017 and 2021. We searched the online databases of the European Patent Office, American Chemical Society, and Google paten... Developing selective CDK2 inhibitors is challenging due to the absence of a previously approved selective CDK2 inhibitor. However, ongoing efforts by Incyte Corporation and Pfizer Inc., which are repo...
A patent review of selective CDK9 inhibitors in treating cancer.
The dysregulation of CDK9 protein is greatly related to the proliferation and differentiation of various cancers due to its key role in the regulation of RNA transcription. Moreover, CDK9 inhibition c... This review focuses on the development of selective CDK9 inhibitors reported in patent publications during the period 2020-2022, which were searched from SciFinder and Cortellis Drug Discovery Intelli... Given that pan-CDK9 inhibitors may lead to serious side effects due to poor selectivity, the investigation of selective CDK9 inhibitors has attracted widespread attention. CDK9 inhibitors make some ad...
An updated patent review of Nrf2 activators (2020-present).
The nuclear factor erythroid 2-related factor 2 (Nrf2) is a pivotal transcription factor that controls the expression of numerous cytoprotective genes and regulates cellular defense system against oxi... This review first discusses the biological effects of Nrf2 and the regulatory mechanism of Kelch-like ECH-associated protein 1-Nrf2-antioxidant response element (Keap1-Nrf2-ARE) pathway. Then, Nrf2 ac... Extensive efforts have been devoted to developing novel Nrf2 activators with improved potency and drug-like properties. These Nrf2 activators have exhibited beneficial effects in...